What is the recommended dosing regimen, treatment duration, and contraindications for Macrobid (nitrofurantoin macrocrystalline) in uncomplicated lower urinary‑tract infection, including considerations for renal impairment, pregnancy, elderly patients, and potential adverse effects?

Macrobid (Nitrofurantoin Macrocrystalline) Dosing and Clinical Guidance

Recommended Dosing Regimen

For uncomplicated lower urinary tract infection (cystitis) in adults, prescribe nitrofurantoin monohydrate/macrocrystals (Macrobid) 100 mg orally twice daily for 5 days. 1

• This 5-day regimen achieves approximately 93% clinical cure and 88% microbiological eradication rates 1
• The standard duration is 5 days; extending beyond 5–7 days provides no additional benefit and increases adverse event risk 1
• For vancomycin-resistant Enterococcus (VRE) causing uncomplicated UTI, use 100 mg orally four times daily 1

---

Absolute Contraindications

Do not prescribe Macrobid when creatinine clearance is below 30 mL/min. 1

• At CrCl <30 mL/min, nitrofurantoin fails to achieve therapeutic urinary concentrations while accumulating systemically, increasing risk of irreversible peripheral neuropathy, pulmonary toxicity, and hepatotoxicity 1
• The American Geriatrics Society explicitly advises avoiding nitrofurantoin in older adults with CrCl <30 mL/min due to heightened toxicity risk 1
• Even short courses (a few days) are unacceptable at this renal function level 1

Do not use Macrobid for suspected or confirmed pyelonephritis (upper tract infection). 1

• Nitrofurantoin does not achieve adequate renal tissue concentrations to treat upper tract infections 1
• If fever >38°C, flank pain, costovertebral angle tenderness, nausea/vomiting, or systemic symptoms are present, prescribe a fluoroquinolone (ciprofloxacin) or third-generation cephalosporin (ceftriaxone) instead 1

---

Renal Impairment Considerations

CrCl 30–60 mL/min (CKD Stage 3a–3b):

• Nitrofurantoin may be used at standard dosing (100 mg twice daily for 5 days) without adjustment 1, 2
• Retrospective data show nitrofurantoin was highly effective in nearly all patients with CrCl 30–60 mL/min, with only two failures attributed to renal insufficiency when CrCl was <30 mL/min 2
• The 2015 Beers Criteria revised the safety cutoff from <60 mL/min to <30 mL/min based on this evidence 1

CrCl ≥60 mL/min:

• Use standard dosing without restriction 1

CrCl <30 mL/min:

• Absolute contraindication—select an alternative agent 1

---

Pregnancy Considerations

Nitrofurantoin is safe and effective throughout most of pregnancy. 1, 3

• Use 100 mg orally twice daily for 5–7 days for symptomatic cystitis or asymptomatic bacteriuria 1
• Avoid in the last three months of pregnancy (after 36 weeks gestation) due to theoretical risk of neonatal hemolytic anemia 3
• Fosfomycin 3 g single dose is the preferred alternative in late pregnancy 1

---

Elderly Patients

Nitrofurantoin is the preferred first-line agent for uncomplicated UTI in elderly patients with normal renal function (CrCl ≥30 mL/min). 1

• It achieves 93% clinical cure and 88% microbiological eradication 1
• Compared with fluoroquinolones and cephalosporins, nitrofurantoin causes minimal disruption of intestinal flora, reducing risk of Clostridioides difficile infection 1
• Verify CrCl before prescribing—many elderly patients have reduced renal function that may not be apparent from serum creatinine alone 1

When CrCl is 26 mL/min (as in your specific question):

• Nitrofurantoin is contraindicated 1
• Alternative options include:
  • Fosfomycin 3 g single dose (no renal adjustment needed for eGFR ≥30 mL/min) 1
  • Trimethoprim-sulfamethoxazole 160/800 mg twice daily for 3 days only if local E. coli resistance is <20% and the patient has not received it in the prior 3 months; however, the American Geriatrics Society advises caution with TMP-SMX when renal function is <30 mL/min 1
  • Fluoroquinolones require renal dose adjustment at CrCl 26 mL/min and should be reserved for culture-proven resistance 1

---

Adverse Effects

Common (5.6–34% of patients): 1

• Nausea (most frequent) 1
• Headache 1
• Diarrhea 1

Serious but rare (<0.001%): 1

• Pulmonary toxicity (acute pneumonitis, chronic interstitial pneumonitis, pulmonary fibrosis)—mainly with long-term use 3, 4
• Peripheral neuropathy—risk increases with renal impairment and prolonged therapy 3, 4
• Hepatotoxicity (0.0003% of cases) 1

Clinical pearls:

• Short-term therapy (5 days) has a favorable safety profile comparable to trimethoprim-sulfamethoxazole and fluoroquinolones 3
• Serious adverse effects are predominantly associated with long-term prophylactic use, not short-course treatment 3, 4
• Ensure adequate hydration during treatment to prevent crystal formation 1

---

When NOT to Use Macrobid

Avoid nitrofurantoin in the following scenarios:

1. Suspected pyelonephritis (fever, flank pain, CVA tenderness) 1
2. CrCl <30 mL/min 1
3. Complicated UTI (structural/functional abnormalities, obstruction, instrumentation) 1
4. Men with suspected prostatitis (nitrofurantoin does not penetrate prostatic tissue) 1
5. Pregnancy after 36 weeks gestation 3
6. Perinephric abscess 1

---

Alternative First-Line Agents (When Nitrofurantoin Cannot Be Used)

Fosfomycin 3 g single oral dose: 1

• Clinical cure ≈91%, with therapeutic urinary concentrations for 24–48 hours 1
• Resistance rates remain low (2.6% in initial infections) 1
• Not appropriate for pyelonephritis or upper tract infections 1

Trimethoprim-sulfamethoxazole 160/800 mg twice daily for 3 days: 1

• Use only when local E. coli resistance is <20% and the patient has not received TMP-SMX in the prior 3 months 1
• Clinical cure ≈93%, microbiological eradication ≈94% when susceptible 1

Reserve fluoroquinolones (ciprofloxacin, levofloxacin) for culture-proven resistant organisms or documented failure of first-line therapy due to serious adverse effects (tendon rupture, peripheral neuropathy, aortic dissection) and rising resistance rates 1

---

Diagnostic Recommendations

Routine urine culture is NOT required for otherwise healthy women with typical lower tract symptoms (dysuria, frequency, urgency) 1

Obtain urine culture and susceptibility testing when: 1

• Symptoms persist after completing therapy
• Symptoms recur within 2–4 weeks
• Fever >38°C, flank pain, or CVA tenderness (suggests pyelonephritis)
• Atypical presentation or vaginal discharge
• Pregnancy
• History of recurrent infections or prior resistant organisms

---

Management of Treatment Failure

If symptoms persist or recur within 2 weeks: 1

• Obtain urine culture and susceptibility testing immediately 1
• Switch to a different antibiotic class for a 7-day course (not the original 5-day regimen) 1
• Assume the original pathogen is resistant to the previously used agent 1
• Reserve fluoroquinolones only for culture-proven resistance 1

If fever persists beyond 72 hours:

• Perform renal ultrasound or CT imaging to exclude obstruction, abscess, or calculi 1

---

Key Clinical Pitfalls to Avoid

1. Do not prescribe nitrofurantoin for "borderline" upper tract symptoms (mild flank pain or low-grade fever)—it is ineffective because the drug does not reach therapeutic concentrations in renal tissue 1

2. Always verify renal function before prescribing—efficacy drops markedly when CrCl falls below 30 mL/min 1

3. Do not treat asymptomatic bacteriuria in non-pregnant patients or those not undergoing urological procedures 1

4. Routine post-treatment urine cultures are unnecessary for asymptomatic patients; obtain cultures only if symptoms persist or recur within 2 weeks 1

5. Do not use empiric fluoroquinolones for simple cystitis—this contributes to rising resistance and should be avoided unless resistance data specifically support their use 1